Nature Communications (Jan 2021)

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells

  • Clément Larrue,
  • Nathan Guiraud,
  • Pierre-Luc Mouchel,
  • Marine Dubois,
  • Thomas Farge,
  • Mathilde Gotanègre,
  • Claudie Bosc,
  • Estelle Saland,
  • Marie-Laure Nicolau-Travers,
  • Marie Sabatier,
  • Nizar Serhan,
  • Ambrine Sahal,
  • Emeline Boet,
  • Sarah Mouche,
  • Quentin Heydt,
  • Nesrine Aroua,
  • Lucille Stuani,
  • Tony Kaoma,
  • Linus Angenendt,
  • Jan-Henrik Mikesch,
  • Christoph Schliemann,
  • François Vergez,
  • Jérôme Tamburini,
  • Christian Récher,
  • Jean-Emmanuel Sarry

DOI
https://doi.org/10.1038/s41467-020-20717-9
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Leukemic stem cells which are resistant to chemotherapy are proposed as relapse-initiating cells (RICs). Here, the authors show that targeting the adrenomedullin-calcitonin receptor-like receptor decreases RICs frequency improving chemotherapy response in AML preclinical models.